My Cart [ 0 ]
Home > Antibodies > Anti-Human Antibodies (In Vivo) > Anti-Human EGFR Monoclonal Antibodies

Anti-Human EGFR Monoclonal Antibodies

ErbB, EC 2.7.10, EC 2.7.10.1, EGFR, mENA, LEGFR, ERBB, ERBB1, HER1, PIG61, NISBD2

Catalog No. Product Name Size List Price (US$) Quantity
PA007575.m1 In Vivo Grade Recombinant Anti-human EGFR Monoclonal Antibody (Clone: 225), Mouse IgG1 Kappa 1 mg 150.00
PA007575.m1 In Vivo Grade Recombinant Anti-human EGFR Monoclonal Antibody (Clone: 225), Mouse IgG1 Kappa 5 mg 350.00
PA007575.m1 In Vivo Grade Recombinant Anti-human EGFR Monoclonal Antibody (Clone: 225), Mouse IgG1 Kappa 25 mg 900.00
Description

PA007575.m1:In Vivo Grade Recombinant Anti-human EGFR Monoclonal Antibody (Clone: 225), Mouse IgG1 Kappa

Recombinant Mouse IgG1 Monoclonal Antibody.
Clone: 225.
Isotype: Mouse IgG1 Kappa.
Source:The anti-human EGFR monoclonal antibody (clone: 225) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 225) specifically binds to human EGFR.
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human EGFR protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The in vivo grade recombinant anti-human EGFR monoclonal antibody of clone 225 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

 

References of anti-human EGFR antibody (Clone: 225):


Near-infrared fluorescent molecular probes with cetuximab in the in vivo fluorescence imaging for epithelial ovarian cancer
Chen, Y., et al. J Ovarian Res. 2024 Nov 14;17(1):138. doi: 10.1186/s13048-024-01547-5. PMID: 39482752
Cetuximab (C225), a monoclonal antibody targeting EGFR, was conjugated with Cy7 for in vivo fluorescence imaging in a subcutaneous SKOV3-Luc xenograft model of epithelial ovarian cancer (EOC) with EGFR overexpression. NIRF imaging with 30 µg cetuximab-Cy7 enabled detection of tumor lesions, with ex vivo analysis showing fluorescence primarily in tumors and lungs compared to controls (PBS, free Cy7, and isotype IgG-Cy7).
Tags: anti-human EGFR 225; anti-human EGFR 225 mAb

Patient-derived xenograft models in cancer therapy: technologies and applications
Zhao, Y., et al. Signal Transduct Target Ther. 2023 Apr 11;8(1):147. doi: 10.1038/s41392-023-01419-2. PMID: 37094868
Patient-derived xenograft (PDX) models from drug-resistant patients identified MET mutations causing cetuximab resistance. These models, generated from therapy-resistant tumor cells, revealed HER2 as a therapeutic target in cetuximab-resistant colorectal cancer, highlighting PDX utility in studying cancer drug resistance mechanisms compared to standard mouse xenografts.
Tags: anti-human EGFR 225 antibody in vivo; anti-human EGFR 225 antibody in animal model

Inhibition of N-acetylglucosaminyltransferase V enhances the cetuximab-induced radiosensitivity of nasopharyngeal carcinoma cells likely through EGFR N-glycan alterations
Chen, Y., et al. Oncol Lett. 2017 Aug;14(2):1521-1528. doi: 10.3892/ol.2017.6319. PMID: 28535302
Cetuximab (C225), an EGFR inhibitor, enhanced radiosensitivity in nasopharyngeal carcinoma (NPC) cells when combined with N-acetylglucosaminyltransferase V (GnT-V) downregulation, which altered EGFR N-glycans. This combination reduced phospho-Akt and phospho-PI3K signaling and decelerated tumor growth in vivo, improving outcomes in CNE-2 cells compared to irradiation or cetuximab alone.
Tags: anti-human EGFR 225 in cancer research; anti-human EGFR 225 antibody in cancer research

Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles
Kim, H., et al. Sci Rep. 2014 Dec 15;4:7808. doi: 10.1038/srep07808. PMID: 25502402
Cetuximab (C225), targeting EGFR-positive non-small cell lung cancer (NSCLC), was conjugated with 14 nm gold nanoparticles (AuNPs), enhancing cytotoxicity in A549 tumor-bearing mice both in vitro and in vivo. Compared to controls (saline, C225 alone, IgG-AuNPs), C225-AuNPs showed superior therapeutic potential for EGFR-positive NSCLC.
Tags: function of anti-human EGFR 225 antibody; bioactivity of anti-human EGFR 225 mAb

In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer
Yang, J., et al. Biomaterials. 2015 Aug;58:1-11. doi: 10.1016/j.biomaterials.2015.04.048. PMID: 26052086
Cetuximab-conjugated vitamin E TPGS micelles enhanced docetaxel delivery in a triple-negative breast cancer (TNBC) xenograft model using EGFR-overexpressing MDA-MB-231/Luc cells in SCID mice. In vivo biodistribution via IVIS® imaging showed improved tumor targeting, requiring a lower M−NP dosage to achieve tumor inhibition comparable to free drug.
Tags: anti-human EGFR antibody 225; clone 225 of anti-human EGFR mAb

 

For more references about anti-human CD3e antibody (225), please contact our scientific support team with message@sydlabs.com.

Related Links

See our Privacy Policy